Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

New Hot Paper Comments

By Warren Olanow

ESI Special Topics, November 2004
Citing URL - http://www.esi-topics.com/nhp/2004/november-04-WarrenOlanow.html

Warren Olanow answers a few questions about this month's new hot paper in the field of Neuroscience & Behavior.

From •>>November 2004

Field: Neuroscience & Behavior
 Article Title: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
 Authors: Olanow, CW;Goetz, CG;Kordower, JH;Stoessl, AJ;Sossi, V;Brin, MF;Shannon, KM;Nauert, GM;Perl, DP;Godbold, J;Freeman, TB
Journal: ANN NEUROL
Volume: 54
Page: 403-414
Year: SEP 2003
* Mt Sinai Sch Med, Dept Neurol, Box 1137, 1 Gustave L Levy Pl, New York, NY 10029 USA.
* Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
* Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
* Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V5Z 1M9, Canada.
* Univ S Florida, Dept Neurosurg, Tampa, FL USA.
* Mt Sinai Sch Med, Dept Pathol, New York, NY USA.
* Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY USA.

ST:  Why do you think your paper is highly cited?

It described a double-blind, controlled evaluation of a treatment that was promising in open-label trials.

ST:  Does it describe a new discovery or new methodology that's useful to others?

It provides a more critical evaluation of this new technology than has been available before.

ST:  Could you summarize the significance of your paper in layman's terms?

It shows that fetal nigral transplantation did not significantly help advanced Parkinson’s disease patients and that said treatment was compromised by potentially serious side effects.

ST:  How did you become involved in this research?

For some time, I have been involved in trying to find a treatment for Parkinson’s disease.End

Warren Olanow, M.D.
Mount Sinai Hospital
Department of Neurology
New York, NY, USA

ESI Special Topics, November 2004
Citing URL - http://www.esi-topics.com/nhp/2004/november-04-WarrenOlanow.html

•> Search Special Topics
New Hot Papers Menu || All Topics Menu
New Hot Papers Comments Menu
Help || About || Contact

ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com
Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.